MedTrace Logo

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

NCT02625935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 206

Last updated 2017-10-13

No results posted yet for this study

Summary

This multicenter, prospectively designed study examines whether the Prosigna score influences physician and patient adjuvant treatment selection over and above currently used prognostic factors. This study also examines the impact of the test results on patients' reported outcomes, including their decisional conflict status and anxiety levels.

Conditions

Sponsors & Collaborators

  • NanoString Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeffrey Vacirca, MD · North Shore Hematology Oncology Associates

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-06-30
Completion
2017-10-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02625935 on ClinicalTrials.gov